Category Press Releases

Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® in U.S. Adults: A Systematic Review

Merck Presents Systematic Review of Pneumococcal Serotypes Covered by CAPVAXIVE® in U.S. Adults Merck & Co., Inc., known as MSD outside the United States and Canada, announced findings from a systematic literature review on the epidemiology and antimicrobial resistance (AMR)…

Read MoreEpidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® in U.S. Adults: A Systematic Review

Samsung Bioepis & Phrontline Forge Global Partnership to Develop Next-Gen ADC Cancer Therapies

Samsung Bioepis and Phrontline Biopharma Enter Global Collaboration to Advance Next-Generation Antibody-Drug Conjugates for Solid Tumors Samsung Bioepis Co., Ltd., a leading global biopharmaceutical company, and Phrontline Biopharma, a clinical-stage biotechnology firm pioneering a new generation of Antibody-Drug Conjugates (ADCs),…

Read MoreSamsung Bioepis & Phrontline Forge Global Partnership to Develop Next-Gen ADC Cancer Therapies

StratifAI Partners with MSK iHub to Validate Polaris™ Using Top Clinical Datasets

StratifAI Selected for MSK iHub Challenge 2025 Cohort to Accelerate Polaris™ Validation Using World-Class Clinical Datasets StratifAI, the AI-driven precision oncology company behind the Polaris™ platform, today announced its selection for the prestigious Memorial Sloan Kettering (MSK) iHub Challenge 2025…

Read MoreStratifAI Partners with MSK iHub to Validate Polaris™ Using Top Clinical Datasets

Atom Therapeutics to Share Positive Clinical Data on Oral Gout Drugs at ACR 2025

Atom Therapeutics to Present Positive Clinical Trial Data for Lead Gout Therapies at ACR Convergence 2025 Atom Therapeutics, a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and metabolic diseases, announced today that it will present two abstracts…

Read MoreAtom Therapeutics to Share Positive Clinical Data on Oral Gout Drugs at ACR 2025

Enamine Helps Discover Promising Broad-Spectrum Coronavirus Antiviral

Enamine Plays Key Role in Discovery of Promising Broad-Spectrum Coronavirus Antiviral Enamine, a leading chemistry and R&D services company, has announced its pivotal contribution to the discovery of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. This milestone was achieved through…

Read MoreEnamine Helps Discover Promising Broad-Spectrum Coronavirus Antiviral